FLNA / Filana Therapeutics, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

EXHIBIT 99.1 Filana Therapeutics Reports Q1 2026 Financial Results and Business Update AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) - Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended Marc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 Filana Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 Filana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2026 Filana Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2026 Filana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-49105 91-1911336 (State or other jurisdiction of incorporation) (Commission

FORM ARS

1 / 117 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ր ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Filana

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of (i) the common stock, $0.001 par value per share ( “Common Stock”), of Filana Therapeutics, Inc. (the “Company”) and (ii) the warrants, each whole warrant exercisable for shares of Common Stock (“Warrants”), of the Company, each of

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Working to advance TSC-related epilepsy program, with a focus on capital efficiency

EXHIBIT 99.1 Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) - Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicine

Policy Regarding Recovery of Erroneously Awarded Compensation Effective October 2, 2023

Exhibit 97 Policy Regarding Recovery of Erroneously Awarded Compensation Effective October 2, 2023 This Policy Regarding Recovery of Erroneously Awarded Compensation (the “Policy”) is established by Filana Therapeutics, Inc.

CASSAVA SCIENCES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement

Exhibit 10.11 CASSAVA SCIENCES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 12, 2025 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Cassava Sciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

INSIDER TRADING POLICY

Exhibit 19.1 INSIDER TRADING POLICY 1. General Purpose Federal securities laws prohibit the purchase or sale of securities by persons who are aware of material nonpublic information about a company, as well as the disclosure of material, nonpublic information about a company to others who then trade in the company’s securities. These transactions are commonly known as “insider trading.” Insider tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Filana Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Filana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Filana Therapeutics, Inc. Subsidiaries

Exhibit 21.1 Filana Therapeutics, Inc. Subsidiaries Subsidiary State/Country of Incorporation/Formation Austin Innovation Park, LLC Texas

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to

Exhibit 99.1 Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under “FLNA” effective March 11, 2026 AUSTIN, TX, March 10, 2026 (GLOBENEWSWIRE) – Cassava Sciences, Inc. (NASDAQ: SAVA) t

CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION CASSAVA SCIENCES, INC.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF CASSAVA SCIENCES, INC. Cassava Sciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby adopts this Certificate of Amendment (this “Certificate of Amendment”), which amends its Amended and Restated Certific

AMENDED AND RESTATED BYLAWS OF FILANA THERAPEUTICS, INC. a Delaware corporation (As amended March 10, 2026) ARTICLE I STOCKHOLDERS

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FILANA THERAPEUTICS, INC. a Delaware corporation (As amended March 10, 2026) ARTICLE I STOCKHOLDERS 1. ANNUAL MEETINGS An annual meeting of stockholders of Filana Therapeutics, Inc. (the “Company”) shall be held for the election of directors at such date and time, as may be designated by resolution of the Board of Directors from time to time. Any other pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 Filana Therapeutic

-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 Filana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Co

Cassava Announces Closure of U.S. Department of Justice Investigation

EXHIBIT 99.1 Cassava Announces Closure of U.S. Department of Justice Investigation AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-41905 91-1911336 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2025 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commissio

Up to $50,000,000 Common Stock

PROSPECTUS SUPPLEMENT (To Prospectus Dated December 5, 2025) Filed Pursuant to Rule 424(b)(2) Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 26, 2025 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 26, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission

CASSAVA SCIENCES, INC. 6801 N. Capital of Texas, Building 1 Suite 300 Austin, TX 78731

CASSAVA SCIENCES, INC. 6801 N. Capital of Texas, Building 1 Suite 300 Austin, TX 78731 December 3, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, DC 20549 Attn: Jessica Dickerson Re: Cassava Sciences, Inc. Registration Statement No. 333-291489 Ladies and Gentlemen: On behalf of Cassava Sciences, Inc. (the “Company”), the undersi

CASSAVA SCIENCES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement

Exhibit 1.2 CASSAVA SCIENCES, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 12, 2025 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Cassava Sciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1.

Calculation of Filing Fee Tables Form S-3 (Form Type) Cassava Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Cassava Sciences, Inc.

As filed with the Securities and Exchange Commission on November 12, 2025

As filed with the Securities and Exchange Commission on November 12, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Cassava Reports Q3 2025 Financials Results and Provides Business Update

EXHIBIT 99.1 Cassava Reports Q3 2025 Financials Results and Provides Business Update Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Further fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors $106.1 million in cash and cash equivalents at September 30, 2025. Expected to sup

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 23, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 23, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Exhibit 99.1 Cassava Sciences Appoints Dawn C. Bir to the Board of Directors AUSTIN, TX, October 22, 2025 (GLOBENEWSWIRE) – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointme

EXHIBIT 99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00

Cassava Reports Q2 2025 Financials Results and Provides Business Update

EXHIBIT 99.1 Cassava Reports Q2 2025 Financials Results and Provides Business Update Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsy Recent appointment of experienced neuroscience leaders to guide the clinical development strategy for simufilam Advanced settlement negotiatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

EXHIBIT 99.1 Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in collaboration with TSC Alliance using a well-accepted Tsc1-knockout model First clinical study for simufilam in TSC-related epilepsy expected to begin in H1 2026 AUSTIN, Texas, Aug. 04, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program

EXHIBIT 99.1 Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human safety data from 1,929 patient Phase 3 program AUSTIN, Texas, June 30, 2025 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechn

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission Fi

Cassava Sciences, Inc. Amended Non-employee Director Compensation Program

Exhibit 10.1 AMENDED NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Adopted and approved effective May 23, 2025) Each member of the Board of Directors (the “Board”) of Cassava Sciences, Inc. (the “Company”), who is not an employee of the Company (each such member, a “Non-employee Director”), will receive the compensation described in this amended Director Compensation Program (the “Amended Director C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-49105 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cassava Sciences, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0

Cassava Reports Q1 2025 Financials Results, Provides Business Update License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at Marc

EXHIBIT 99.1 Cassava Reports Q1 2025 Financials Results, Provides Business Update License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-sta

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Exhibit 99.1 Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development AUSTIN, TX, April 21, 2025 (GLOBENEWSWIRE) – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for cent

Amended and Restated Employment Agreement, dated April 18, 2025, by and between Cassava Sciences, Inc. and Eric J. Schoen

Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made this 18th day of April 2025 (the “Effective Date”), by and between CASSAVA SCIENCES, INC., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (“Cassava” or “Company”), and ERIC SCHOEN, an individual (“Schoen” or “Executive”). Thi

Amended and Restated Employment Agreement, dated April 18, 2025, by and between Cassava Sciences, Inc. and R. Christopher Cook

Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made this 18th day of April 2025 (the “Effective Date”), by and between CASSAVA SCIENCES, INC., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (“Cassava” or “Company”), and ROBERT CHRISTOPHER COOK, an individual (“Cook” or “Execut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission F

ARS

1 / 122 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Cassav

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

EXHIBIT 99.1 Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease Simufilam continued to demonstrate an overall favorable safety profile Cassava’s Alzheimer’s disease development program with simufilam will be completely

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan (As Amended and Restated on March 6, 2025)

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW. CASSAVA SCIENCES, INC. 2020 CASH INCENTIVE BONUS PLAN [As Amended by the Board of Directors and Approved by the Delaware Court of Chancery Effectiv

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29

Subsidiaries of the Registrant.

Exhibit 21.1 Cassava Sciences, Inc. Subsidiaries Subsidiary State/Country of Incorporation/Formation Austin Innovation Park, LLC Texas

Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY 1. General Purpose Federal securities laws prohibit the purchase or sale of securities by persons who are aware of material nonpublic information about a company, as well as the disclosure of material, nonpublic information about a company to others who then trade in the company’s securities. These transactions are commonly known as “insider trading.” Insider tr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission Fi

Description of Registrant’s Securities.

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of (i) the common stock, $0.001 par value per share ( “Common Stock”), of Cassava Sciences, Inc. (the “Company”) and (ii) the warrants, each whole warrant exercisable for shares of Common Stock (“Warrants”), of the Company, each of whi

Employment Agreement, executed on November 18, 2024, by and between Registrant and Freda Nassif

Exhibit 10.24 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made this 15th day of November 2024, by and between CASSAVA SCIENCES, INC., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (“Cassava” or “Company”), and FREDA NASSIF, an individual (“Nassif” or “Executive”). Executive’s first day of employment will be November 18, 2024 (

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

EXHIBIT 99.1 Cassava Sciences Reports 2024 Financial Results and Provides Business Update Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025 License agreement brings potential in a new therapeutic application for simufilam for seizures related to tuberous sclerosis complex (TSC) $128.6 Million in Cash a

Policy Regarding Recovery of Erroneously Awarded Compensation

Exhibit 97 Policy Regarding Recovery of Erroneously Awarded Compensation Effective October 2, 2023 This Policy Regarding Recovery of Erroneously Awarded Compensation (the “Policy”) is established by Cassava Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Sciences Licenses Simufilam Method of Treatment Patent ● Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental disorders ● The licensed patent is based on research led by Yale University and published in Science Translational Medicine showing that treatment with simufilam appeared to meaningfully reduce seizure frequency in an animal model ● Cassava will prioritize initial development efforts on tuberous sclerosis complex (TSC)-related seizures AUSTIN, Texas (GLOBE NEWSWIRE) – February 27, 2025 – Cassava Sciences, Inc.

License Agreement, dated February 26, 2025, by and between Cassava Sciences, Inc. and Yale University

Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. THIS LICENSE AGREEMENT (the “AGREEMENT”) by and between YALE UNIVERSITY, a corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecti

Cassava Sciences Provides a Business Update Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a

EXHIBIT 99.1 Cassava Sciences Provides a Business Update Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment including a workforce reduction of approximately 33% Approximately $128.6 million cash and cash equivalents at December 31, 2024 (unaudited) AUSTIN,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

SAVA / Cassava Sciences, Inc. / Nachtrab Matthew - FILING AND EX-99CERT

begin 644 Filing.pdf M)5!$1BTQ+C0*)=/KZ>$*,2 P(&]B:@H\/"]4:71L92 H;VYL:6YE9F]R;7,N M961G87)F:6QI;F@/XC"1MT06U9;G']'0& JVQT%9$N [Y- P0;@#-OT9=F;8 M#<(XP;L]'MC-[V;)6]PV 1:P#IUA@SQZ>%1I,D)Q]@4T3!1V:-&"1D5&84J M&N7IU) HHU/!P,#$1$=!0T%A%Y5JW&>R7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ M\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+\0 M1$ @$"! 0# M! <%! 0

SAVA / Cassava Sciences, Inc. / Nachtrab Matthew - TRANSFER TO IRREV TRUST

begin 644 EX1.pdf M)5!$1BTQ+C8-)>+CS],-"C(W(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#,@,5T^/G-T R4\@DL4,1+)^!I$,(2"2P-85@=$%ET'ZUH))!DG/0*+ MGP*1GJU@M@:(U,P!LXO ;#\@^=]^&0,3T,958#,9&*E,F=@O/$)(, %#81 M/PT*96YDI)9M;ZI(%,>RKQLTS3,\PS) M31.MUUN[K=N(NW9C?$$K:TD0#-#L^NWWS"#*8*6M&Z+ .6?F'.;FP< M(4$1UXCZ''$?<::1 #.72! DA&<%:)4 M8B2@*PY]04NJH2 MHDLO>-]LDF@-;H1O;J!-KW@U+P1CX=V.!D%4(D:A[HEW&V[NHGCU5B*%L3>( MJL!K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3

EXHIBIT 99.1 Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s disease in the ReThink-ALZ Phase 3 study Simufilam continued to demonstrate an overall favorable safety profile Cassava intends to present the data at an upcoming medical m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe

Cassava Sciences Reports Q3 2024 Financial and Operating Results

EXHIBIT 99.1 Cassava Sciences Reports Q3 2024 Financial and Operating Results Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq

SAVA / Cassava Sciences, Inc. / BARBIER REMI - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 20) * Cassava Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14817C 107 (CUSIP Number) Eric Schoen – Chief Financial Officer 6801 N Capital of Texas Highway, Building 1 Suite 300, Austin, TX 78731 (512) 501-2450 (N

An Open Letter from President and CEO Rick Barry to the Cassava Community: Patients and their Loved Ones, Caregivers, Principal Investigators, Shareholders and Employees October 8, 2024

Exhibit 99.1 An Open Letter from President and CEO Rick Barry to the Cassava Community: Patients and their Loved Ones, Caregivers, Principal Investigators, Shareholders and Employees October 8, 2024 A lot has happened in the few months since I last wrote to you. It’s time that I update you on what has taken place here at Cassava and the substantial progress that we have made. I am happy to inform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 6, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 6, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorp

Executive Employment Agreement, dated October 1, 2024.

Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is made this 1st day of October, 2024, by and between CASSAVA SCIENCES, INC., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (“Cassava” or “Company”), and RICHARD J. BARRY, an individual (“Barry” or “Executive”). 1. Position and Duties. a. Position. Executive has been appoin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2024 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commissio

Cassava Sciences Resolves SEC Investigation

Exhibit 99.1 Cassava Sciences Resolves SEC Investigation AUSTIN, Texas – September 26, 2024 – Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed S

Barbier Consulting Agreement dated September 13, 2024

Exhibit 10.1 CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) is made this 13th day of September, 2024, by and between Cassava Sciences, Inc., 6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731 (“Cassava” or “Company”), and Remi Barbier, an individual (“Barbier” or “Consultant”). WHEREAS, Barbier and the Company are parties to an Employment Agreement dated July 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2024 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commissio

Cassava Sciences Names Rick Barry as Chief Executive Officer Claude Nicaise, M.D. appointed Chairman of the Board

EXHIBIT 99.1 Cassava Sciences Names Rick Barry as Chief Executive Officer Claude Nicaise, M.D. appointed Chairman of the Board AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

SAVA / Cassava Sciences, Inc. / Nachtrab Matthew - CALCULATION OF BENEFICIAL OWNERSHIP

begin 644 exhibitd.pdf M)5!$1BTQ+C8-)>+CS],-"C4R(# @;V)J#3P\+TQI;F5AF4@,3$P+U1Y<&4O6%)E9B]76S$@,R Q73X^ 9?O Y'NP2!*8Y "+7 .3AT DHQ)8 MO S,K@61ZM)@D4=@DT- )/]'L*P.B&Q;!I9]#B09MY6#S3$!D9H'P>)-('&/ M!K!Z#1"IZPUFKP:1YO5@MB&0-?]F($)Z(O#8%L8& <%^9^!Z?5+@ # += M&)H-"F5N9'-T!H0!:3@V(&AA & 48SUOM,/$Q63+.9^!BW,#4QY3&< M8U)BT%0[SMC'P, WE^%&:Q#CY&W*C \T5E8%IUC:H*@6 , [8T7UPT*96YDK2*46$T$(]80Q@VQ MEC#CB'5$<2"D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorpora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

EXHIBIT 99.1 Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates $207.3 Million in Cash and Cash Equivalents at June 30, 2024. Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution. Conference Webcast Scheduled for Today at 8:30AM ET. AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) - Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2024 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

An Open Letter from Executive Chairman Rick Barry to the Cassava Community: Shareholders, Employees, Principal Investigators, Patients and their Loved Ones July 21, 2024

Exhibit 99.1 An Open Letter from Executive Chairman Rick Barry to the Cassava Community: Shareholders, Employees, Principal Investigators, Patients and their Loved Ones July 21, 2024 By now, I suspect that many of you have seen the news that Cassava Sciences released last week about our change in leadership. As we announced, I have taken on the roles of Executive Chairman of the Board and, in this

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE CASSAVA SCIENCES INC. 2020 CASH INCENTIVE PLAN DERIVATIVE LITIGATION C.A. No. 2022-0737-MTZ NOTICE OF PENDENCY OF SETTLEMENT OF CLASS AND DERIVATIVE ACTION TO: ALL CURRENT STOCKHOLDERS OF CASSAVA SCIENCES INC. (“CASSAVA” OR THE “COMPANY,” TRADING SYMBOL: SAVA) AND ANY STOCKHOLDERS WHO OWNED CASSAVA STOCK AT ANY TIME BETWEEN AND I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2024 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Exhibit 99.1 Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives ● Rick Barry appointed Executive Chairman of the Board ● Remi Barbier resigns as President and CEO and from the Board of Directors ● Cassava initiates search for a new CEO Austin, Texas, July 17, 2024 – Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 01, 2024 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 01, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

Employment agreement amendment, dated May 20, 2024, by and between Cassava Sciences, Inc. and Eric J. Schoen

Exhibit 10.1 [Cassava Sciences, Inc. letterhead] Amendment to Employment Agreement On May 20, 2024, the Compensation Committee of the Board of Directors of Cassava Sciences, Inc. directed that the employment agreement for Eric Schoen (“the Executive”) shall be immediately amended to include a ‘change-in-control’ clause. This amendment (the “Amendment”) is therefore made between the Executive and C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2024 Cassava Sciences, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2024 Cassava Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission File

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

EXHIBIT 99.1 Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam $126.3 Million In Total Gross Proceeds from Warrant Distribution. Over 1,900 Patients with Alzheimer’s Disease Are Randomized in Phase 3 Trials of Simufilam. Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) - Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share

EXHIBIT 99.1 Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company”), a biotechnology company focused on Alzheimer’s disease, today announced total gross pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Cassava Sciences, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File

EX-99.25

Savaw-form25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Cassava Sciences, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File

Notice of Guaranteed Delivery for Exercise of Warrants of Cassava Sciences, Inc. (Not to be used for Signature Guarantees)

Exhibit 99.2 Notice of Guaranteed Delivery for Exercise of Warrants of Cassava Sciences, Inc. (Not to be used for Signature Guarantees) On April 15, 2024, Cassava Sciences, Inc. (the “Company”) gave notice that it is redeeming, on May 7, 2024 (the “Redemption Date”), all of the Company’s outstanding Warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per sh

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

EXHIBIT 99.1 Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ. Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants. ‘Notice of Guaranteed Delivery’ Is Available for Warrant Exercises. AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (NASDAQ:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Redemption Date Announced for Warrants

EXHIBIT 99.1 Redemption Date Announced for Warrants Monday, May 6, 2024 is Last and Final Day to Exercise Warrants. Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ☑ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.

ARS

1 / 119 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Cassav

Policy Regarding Recovery of Erroneously Awarded Compensation

Exhibit 97. Policy Regarding Recovery of Erroneously Awarded Compensation Effective October 2, 2023 This Policy Regarding Recovery of Erroneously Awarded Compensation (the “Policy”) is established by Cassava Sciences, Inc. (the “Company”), a Delaware corporation, effective as of October 2, 2023 (the “Effective Date”). 1. Purpose. The Company is committed to promoting high standards of honest and e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29

Description of Registrant’s Securities.

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a brief description of (i) the common stock, $0.001 par value per share ( “Common Stock”), of Cassava Sciences, Inc. (the “Company”) and (ii) the warrants, each whole warrant exercisable for shares of Common Stock (“Warrants”), of the Company, each of whi

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

EXHIBIT 99.1 Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates $121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants. A Total of Over 555 Study Participants Have Completed Our Phase 3 Studies. Topline Data Readout for Our 52-Week Phase 3 Trial Expected Year-End 2024. Internal Investi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Subsidiaries of the Registrant.

Exhibit 21.1 Cassava Sciences, Inc. Subsidiaries Subsidiary State/Country of Incorporation/Formation Austin Innovation Park, LLC Texas

SAVA / Cassava Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Cassava Sciences Inc Title of Class of Securities: Common Stock CUSIP Number: 14817C107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

EXHIBIT 99.1 No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Ba

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

SAVA / Cassava Sciences, Inc. / BARBIER REMI - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 19) * Cassava Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 14817C 107 (CUSIP Number) Eric Schoen – Chief Financial Officer 6801 N Capital of Texas Highway, Building 1 Suite 300, Austin, TX 78731 (512) 501-2450 (N

SAVA / Cassava Sciences, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us14817c1071012624.txt us14817c1071012624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) CASSAVA SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14817C107 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b

Warrant Agreement (including Form of Warrant), dated January 3, 2024, between Cassava Sciences, Inc., Computershare Inc., and Computershare Trust Company, N.A.

Exhibit 4.1 WARRANT AGREEMENT Dated as of January 3, 2024 between CASSAVA SCIENCES, INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent Warrants for Shares of Common Stock of Cassava Sciences, Inc. TABLE OF CONTENTS Page Article I Definitions Section 1.01 Definitions 4 Section 1.02 Other Definitions 9 Section 1.03 Rules of Construction.: 9 Article II Form of Warrant;

25,342,150 Common Shares

Filed Pursuant to Rule 424(b)(2) Registration No. 333-271542 Prospectus Supplement (To Prospectus dated May 1, 2023) 25,342,150 Common Shares This prospectus supplement relates to the issuance and sale of up to 25,342,150 shares of Common Stock, par value $0.001 per share (the “Common Stock”), by Cassava Sciences, Inc. (“Cassava” or the “Company”) upon the exercise of warrants issued by Cassava on

CERT

The Nasdaq Stock Market LLC, 805 King Farm Blvd., Rockville, MD 20850 Eun Ah Choi Senior Vice President U.S. Listing Qualifications & Market Surveillance January 3, 2024 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Division of Corporation Finance: This is to certify that on January 2, 2024, The Nasdaq Stock Market LLC (the "Excha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Cassava Sciences, Inc. (Exact name of registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 91-1911336 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 6801 N Capital of

CALCULATION OF REGISTRATION FEE

Exhibit 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Share(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.

Form of Warrant Agreement between Computershare Inc., and its affiliate, Computershare Trust Company, N.A. and the Registrant (including the form of the Warrants)

Exhibit 4.1 FORM OF WARRANT AGREEMENT Dated as of January , 2024 between CASSAVA SCIENCES, INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent Warrants for Shares of Common Stock of Cassava Sciences, Inc. TABLE OF CONTENTS Page Article I Definitions Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Rules of Construction.: 6 Article II Form of W

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Cassava Sciences, Inc. (Exact name of registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 91-1911336 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 6801 N Capital of

Form of Warrant Agreement between Computershare Inc., and its affiliate, Computershare Trust Company, N.A. and the Registrant (including the form of the Warrants)

Exhibit 4.1 FORM OF WARRANT AGREEMENT Dated as of January , 2024 between CASSAVA SCIENCES, INC. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A. as Warrant Agent Warrants for Shares of Common Stock of Cassava Sciences, Inc. TABLE OF CONTENTS Page Article I Definitions Section 1.01 Definitions 1 Section 1.02 Other Definitions 5 Section 1.03 Rules of Construction.: 6 Article II Form of W

###

Exhibit 99.2 Dear Stockholder – I’m pleased to inform you that on December 12, 2023, Cassava Sciences announced a pro rata distribution of warrants to its stockholders. The warrants will allow the holder to purchase additional shares of Cassava Sciences common stock, if they wish to do so. With this Q&A, I would like to make the warrant distribution a subject of conversation, and answer some of yo

Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders

Exhibit 99.1 Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders ■ Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock ■ All Warrants to Be Distributed to Shareholders Free of Charge ■ Warrants Are Expected to List and Trade on Nasdaq ■ Warrant Holders Who Choose to Exercise During an Early Period Will Also Receive an Additional 0.5 of a Common

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2023 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2023 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

Cassava Sciences Appoints Three New Members to its Board of Directors Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government.

Exhibit 99.1 Cassava Sciences Appoints Three New Members to its Board of Directors Dr. Nicaise, Mr. Gravier and Mr. Anderson have years of experience in drug development, healthcare M&A and working with the U.S. Government. AUSTIN, Texas – December 7, 2023 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Numbe

Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

EXHIBIT 99.1 Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials. Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025. MRI safe

Amended and Restated Bylaws of Cassava Sciences, Inc.

 Exhibit 3.4  AMENDED AND RESTATED BYLAWS OF CASSAVA SCIENCES, INC. a Delaware corporation (As amended September 8, 2023)  ARTICLE I STOCKHOLDERS 1 . ANNUAL MEETINGS An annual meeting of stockholders of Cassava Sciences, Inc. (the “Company”) shall be held for the election of directors at such date, time and place, either within or without the state of Delaware, as may be designated by resolutio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2023 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

LETTER

United States securities and exchange commission logo August 14, 2023 Eric Schoen Chief Financial Officer Cassava Sciences, Inc.

, 2023

  August 10, 2023  VIA EDGAR  Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.

Cassava Sciences Non-Employee Director Compensation Plan

Exhibit 10.3   non-employee DIRECTOR COMPENSATION program (Adopted and approved effective May 4, 2023) Each member of the Board of Directors (the “Board”) of Cassava Sciences, Inc. (the “Company”), who is not an employee of the Company (each such member, a “Non-employee Director”), will receive the compensation described in this Director Compensation Program (the “Director Compensation Program”)

Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan (As Amended March 16, 2023).

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. SUCH PORTIONS ARE MARKED AS INDICATED WITH BRACKETS (“[***]”) BELOW. Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan [As Amended by the Board of Directors Effective March 16, 2023] This 2020 Cash Incentive Bonu

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassava Sc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

EXHIBIT 99.1 Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023. Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months. Completion of patient enrollment for Phase 3 program still exp

LETTER

United States securities and exchange commission logo July 28, 2023 Eric Schoen Chief Financial Officer Cassava Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 Cassava Sciences, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission Fil

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease

EXHIBIT 99.1 Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild Alzheimer’s, Simufila

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2023 Cassava Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 4, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Cassava Sciences, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File

Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

EXHIBIT 99.1 Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam. Completion of patient enrollment for Phase 3 program still expected Q4 2023. $187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-st

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission Fi

As filed with the Securities and Exchange Commission on May 1, 2023

As filed with the Securities and Exchange Commission on May 1, 2023 Registration No.

Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassava S

Up to $200,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-271542 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 1, 2023) Up to $200,000,000 Common Stock On May 1, 2023, we entered into a sales agreement with JonesTrading Institutional Services LLC, or the Agent, relating to the shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales

Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Cassava Sciences, Inc.

Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Cassava Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Cassava Sciences, Inc.

Capital On DemandTM Sales Agreement, dated as of May 1, 2023, between Cassava Sciences, Inc. and JonesTrading Institutional Services LLC

Exhibit 1.1 CASSAVA SCIENCES, INC. Common Stock ($0.001 par value per share) Capital On DemandTM Sales Agreement May 1, 2023 JonesTrading Institutional Services LLC 211 East 43rd Street, 15th Floor New York, NY 10017 Ladies and Gentlemen: Cassava Sciences, Inc. a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent

Schedule 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2023 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission Fi

ARS

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Cassava Scie

Record Date and Share Ownership Post-Employment Obligations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant þ Filed by a party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 Cassava Sciences, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission Fi

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

EXHIBIT 99.1 Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates In Q2 2023, We Expect to Complete Patient Dosing for our Cognition Maintenance Study in Alzheimer’s disease. In Q3 2023, We Expect to Announce Results of our Cognition Maintenance Study. In Q4 2023, We Expect to Complete Patient Enrollment for our Phase 3 Studies of Simufilam in Alzheimer’s disease. Mid-ye

Subsidiaries of the Registrant.

Exhibit 21.1 Cassava Sciences, Inc. Subsidiaries   Subsidiary State/Country of Incorporation/Formation  Austin Innovation Park, LLC Texas 

Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Cassava Scienc

Amended and Restated Bylaws of Cassava Sciences, Inc.

Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF CASSAVA SCIENCES, INC. a Delaware corporation TABLE OF CONTENTS  Page ARTICLE I STOCKHOLDERS 2  1. ANNUAL MEETINGS 2  2. SPECIAL MEETINGS 2  3. NOTICE OF MEETINGS 2  4. ADVANCE NOTICE OF STOCKHOLDER NOMINEES AND STOCKHOLDER BUSINESS 2  5. ADJOURNMENTS 2  6. QUORUM 2  7. ORGANIZATION 2  8. VOTING; PROXIES 3  9. FIXING DATE FOR DETERMINATION OF ST

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Cassava Science

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

SAVA / Cassava Sciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Cassava Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14817C107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

SAVA / Cassava Sciences Inc / PAIN THERAPEUTICS INC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 18) * Cassava Sciences, Inc. (Name of Issuer) Common Stock, $0.001 per value share (Title of Class of Securities) 14817C 107 (CUSIP Number) Eric Schoen – Chief Financial Officer 6801 N Capital of Texas Highway, Building 1 Suite 300, Austin,

SAVA / Cassava Sciences Inc / BlackRock Inc. Passive Investment

us14817c1071020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) CASSAVA SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14817C107 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

EXHIBIT 99.1 Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease ADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patien

Certificate of Amendment of Amended and Restated By-laws of Cassava Sciences, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED BYLAWS OF CASSAVA SCIENCES, INC. The undersigned, R. Christopher Cook, hereby certifies that: 1.I am the duly elected and incumbent Secretary of Cassava Sciences, Inc., a Delaware corporation (the “Corporation”). 2.By resolution of the Board of Directors of the Corporation duly adopted at a meeting duly called and held on December 19, 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2022 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2022 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

Form of Securities Purchase Agreement, dated November 18, 2022, by and between Cassava Sciences, Inc. and the purchasers named therein

EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 18, 2022, between Cassava Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio

Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

 Exhibit 99.2 Cassava Sciences Announces Closing of $50 Million Registered Direct Offering  AUSTIN, Texas, Nov. 22, 2022 – Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at

Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

 Exhibit 99.1 Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock  AUSTIN, Texas, Nov. 18, 2022 – Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional in

Calculation of Filing Fee Table (Form Type) CASSAVA SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Table 1: Newly Registered Securities

EXHIBIT 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) CASSAVA SCIENCES, INC.

CASSAVA SCIENCES, INC. 1,666,667 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-252931 PROSPECTUS SUPPLEMENT (to the Prospectus dated February 10, 2021) CASSAVA SCIENCES, INC. 1,666,667 Shares of Common Stock We are offering 1,666,667 shares of our common stock at a price of $30.00 per share to certain institutional and accredited investors pursuant to this prospectus supplement and the accompanying prospectus. Our common

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassa

Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates – $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzhe

EXHIBIT 99.1 Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates – $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Cassava Sciences

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign

Exhibit 99.1 Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign  AUSTIN, Texas – November 3, 2022 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ page complaint alleges t

Employment Agreement, executed on October 13, 2022, by and between Registrant and R. Christopher Cook

PERSONAL AND CONFIDENTIAL       Exhibit 10.1 October 12, 2022  Mr. R. Christopher Cook XXXXXXXX XXXXXXXX   Dear Chris:  On behalf of the Board of Directors of Cassava Sciences, Inc., (the “Company”) I am pleased to extend you an offer of employment as Senior VP and General Counsel (“GC”), an officer-level position. This Letter Agreement is intended to set forth the terms and conditions o

Cassava Sciences Announces Expansion of Leadership Team

     Exhibit 99.1 Cassava Sciences Announces Expansion of Leadership Team  · Chris Cook, A Skilled Litigator, To Join Management Team as General Counsel · New Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas – October 27, 2022 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 13, 2022 Cassava Sciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 13, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 22, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commissio

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassava Sc

Amendment 1 to 2018 Omnibus Incentive Plan

Exhibit 10.1 ? AMENDMENT NO. 1 TO THE CASSAVA SCIENCES, INC. 2018 OMNIBUS INCENTIVE PLAN This Amendment No. 1 to the Cassava Sciences, Inc. 2018 Omnibus Incentive Plan (the ?Plan?) is effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company. Capitalized but undefined terms shall have the meanings set forth in the Plan. ? 1. The name of the

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

EXHIBIT 99.1 Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

EXPLANATORY NOTE

EXHIBIT 107 EXPLANATORY NOTE This filing is being made pursuant to Rule 424(b)(5) and Rule 424(b)(8) under the Securities Act of 1933, as amended, solely to add the Calculation of Filing Fee table with respect to the Prospectus Supplement dated February 10, 2021 filed by Cassava Sciences, Inc.

EXPLANATORY NOTE

Filed Pursuant to Rule 424(b)(5) and Rule 424(b)(8) Registration No. 333-252931 EXPLANATORY NOTE This filing is being made pursuant to Rule 424(b)(5) and Rule 424(b)(8) under the Securities Act of 1933, as amended, solely to add the Calculation of Filing Fee table with respect to the Prospectus Supplement dated February 10, 2021 filed by Cassava Sciences, Inc. with the Securities and Exchange Comm

Filing Fee Table

EX-FILING FEES 4 sava-20220610xex10.htm EX-107 Exhibit 107  Calculation of Filing Fee Tables  Form S-8 (Form Type)  Cassava Sciences, Inc. (Exact Name of Registrant as Specified in its Charter)  Table 1: Newly Registered Securities   Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate

As filed with the Securities and Exchange Commission on June 10, 2022

As filed with the Securities and Exchange Commission on June 10, 2022 ? Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission File

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassava S

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program - $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program -

EXHIBIT 99.1 Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program - $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today a

Cassava Sciences, Inc.

Exhibit 99.1 April 26, 2022 Letter To Science Editor of the New York Times: Regarding The New York Times article, ?Scientists Question Data Behind an Experimental Alzheimer?s Drug?, by Apoorva Mandavilli (April 18, 2022): we?re disappointed the reporter relied almost exclusively on sources known to be critical of Cassava Sciences, failed to report on conflicts of interests and misrepresented our C

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240.

1 See: FDA Grants Accelerated Approval for Alzheimer’s Drug, June 07, 2021, https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 Cassava Scienc

Form of Indemnification Agreement between Registrant and each of its directors and officers.

Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of this day of , 202, by and between CASSAVA SCIENCES, INC., a Delaware corporation (the ?Company?), and (?Indemnitee?). WHEREAS, the Company and Indemnitee recognize the increasing difficulty in obtaining directors? and officers? liability insurance, the significant increases in the cost of such insuran

Subsidiaries of the Registrant.

Exhibit 21.1 Cassava Sciences, Inc. Subsidiaries ? ? Subsidiary State/Country of Incorporation/Formation ? Austin Innovation Park, LLC Texas ?

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

EXHIBIT 99.1 Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer?s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates. ?In second half 2021, we initiated

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

SAVA / Cassava Sciences Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Cassava Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 14817C107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ R

SAVA / Cassava Sciences Inc / BlackRock Inc. Passive Investment

us14817c1071020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) CASSAVA SCIENCES INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 14817C107 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

SAVA / Cassava Sciences Inc / BARBIER REMI - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. 17) * Cassava Sciences, Inc. (Name of Issuer) Common Stock, $0.001 per value share (Title of Class of Securities) 14817C 107 (CUSIP Number) Eric Schoen ? Chief Financial Officer 7801 N Capital of Texas Highway, Suite 260 Austin, TX 78731 (51

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 5, 2022 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission F

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassa

Agreement of Sale and Purchase Between DWF IV Lakewood, LP and Cassava Sciences, Inc. dated July 2, 2021

Exhibit 10.4 ? Note: Certain identified information, [***], in this Exhibit 10.4 has been excluded from the exhibit as that information (i) is not material and (ii) would likely result in competitive harm to the registrant if publicly disclosed. ? AGREEMENT OF SALE AND PURCHASE ? BETWEEN ? DWF IV LAKEWOOD, LP, a Delaware limited partnership ? ?Seller? ? and ? CASSAVA SCIENCES, INC., a Delaware cor

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commissio

Cassava Sciences Reports Third Quarter 2021 Financial Results

EXHIBIT 99.1 Cassava Sciences Reports Third Quarter 2021 Financial Results AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer?s disease, today announced financial results for the third quarter ended September 30, 2021. Net loss for the third quarter ended September 30, 2021, was $9.6 million, or $0.24 p

Master Services Agreement between Cassava Sciences, Inc. and Premier Research International LLC, dated June 11, 2021

Exhibit 10.3 Note: Certain identified information, [***], in this Exhibit 10.3 has been excluded from the exhibit as that information (i) is not material and (ii) would likely result in competitive harm to the registrant if publicly disclosed. ? Master Services Agreement ? This Master Services Agreement (the ?Agreement?) is made and entered on this 11th day of June 2021, (the ?Effective Date?), by

Item 4. Mine Safety Disclosures Item 5. Other Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-29959 Cassava Sc

Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease

Exhibit 99.2 ? Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer?s Disease ? ? Simufilam Significantly Improves Cognition in Patients with Alzheimer?s in Interim Analysis of Open-label Study at 9 Months ? ? Cognition Improved 3.0 Points on ADAS-Cog at 9 Months (p<0.001) ? ? Cognitive Improvements Track with Biomarker Improvements ? ? No Behavior Disorders in Over 50% o

Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer’s Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Brignoni, Boris Nikolov, Hoau-Yan Wang,

Exhibit 99.1 ? Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer?s Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Brignoni, Boris Nikolov, Hoau-Yan Wang, Zhe Pei, Antonio Hernandez, Carrie A. Crowley, Nadav Friedmann Alzheimer?s association AAIC>21 CASSAVA sciences 1 ? Forward-Looking Sta

Cassava Sciences Reports Second Quarter 2021 Financial Results - Conference Call Today at 9 a.m. ET -

EXHIBIT 99.1 Cassava Sciences Reports Second Quarter 2021 Financial Results - Conference Call Today at 9 a.m. ET - AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer?s disease, today announced financial results for the second quarter ended June 30, 2021. Net loss for the second quarter ended June 30, 20

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease

Exhibit 99.3 ? Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer?s Disease ? ? Simufilam Significantly Improved Biomarkers in Alzheimer?s Patients Treated for 6 Months ? ? Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p< 0.00001) ? ? Biomarker Improvements Track with Cognitive Improvements ? ? Oral Presentation

 Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease - Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s Disease

Exhibit 99.1 ? ? ? Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer?s Disease ? - Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer?s Disease - ? AUSTIN, Texas ? June 21, 2021 ? Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer?s disease,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission F

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –

Exhibit 99.1 ? Cassava Sciences Announces the Appointment of ? Richard J. Barry to its Board of Directors ? - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals ? ? AUSTIN, Texas ? June 14, 2021 ? Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer?s disease, today announced the appo

Regulation FD Disclosure, Financial Statements and Exhibits

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission F

Submission of Matters to a Vote of Security Holders

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 000-29959 91-1911336 (State or other jurisdiction of incorporation) (Commission Fil

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Form 10-Q ? ? (Mark One) ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) ? OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the Quarterly Period Ended March 31, 2021 or ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) ? OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to ? Commission File Number:

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 21, 2021 Cassava Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release - 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Ini

EXHIBIT 99.1 Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release - 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2nd Half 2021 - - Initiation of Cognition Maintenance Study On-track for June 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Schedule 14a of the Securities Exchange Act Of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240.

Annual Report - 10-K

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? Form 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29959 ?

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

EXHIBIT 99.1 Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) - Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were a

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 23, 2021 Cassava Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 000-29959 91-1911336 (State or Other Jurisdiction of Incorporation) (Commission F